May 28, 2026
FOCUS on Drug Repurposing. Montelukast is a cysteinyl leukotriene receptor (CysLTR1) antagonist currently in use for asthma. In a paper just out in Nature Cancer, a […]
May 8, 2026
FOCUS on PROTACs. On May 1st the first PROTAC, a heterobifunctional protein degrader and a new therapeutic modality, was approved by the FDA. Vepdegestrant (Arvinas’ Veppanu) […]
April 30, 2026
FOCUS on Pancreatic Cancer. In a paper just out in Nature Medicine, the team at Actuate Therapeutics reported the results of their Phase II trial on […]
April 27, 2026
Focus Biomolecules is delighted to announce our 2026 AACR Travel Grant awardees, Shujah Rehman (grad student at The University of Kansas) and Nabamita Boruah (postdoc at […]
April 17, 2026
FOCUS on New Cancer Therapeutic Targets. Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality and is largely driven by metabolic disorders such as obesity […]
April 14, 2026
Focus Biomolecules will be exhibiting at the annual meeting of American Association for Cancer Research in San Diego, April 19 – 22. Stop by our booth […]
March 12, 2026
FOCUS on a New Pharma Success Story. Day One Biopharmaceuticals is only 8 years old, yet in that short period of time it bought the rights […]
March 4, 2026
FOCUS on new drug approvals. On February 24th the FDA granted approval to Encorafenib (Braftovi, Array Biopharma, a subsidiary of Pfizer) in combination with cetuximab and […]
February 27, 2026
Will you be attending the AACR (American Association for Cancer Research) Annual Meeting 2026 in San Diego this April? Focus Biomolecules will be awarding two travel […]